This HTML5 document contains 169 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34600089
rdf:type
wikibase:Item
schema:description
سائنسی مضمون article científic 2008年論文 სამეცნიერო სტატია 2008年の論文 vitskapeleg artikkel wissenschaftlicher Artikel επιστημονικό άρθρο article scientifique (publié 2008) mokslinis straipsnis 2008년 논문 2008年论文 artigo científico teaduslik artikkel ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2008年论文 2008 nî lūn-bûn wetenschappelijk artikel vitenskapelig artikkel artikull shkencor 2008年論文 مقالة علمية научни чланак tieteellinen artikkeli scientific article 2008年论文 videnskabelig artikel (udgivet 2008) article scientific мақолаи илмӣ bilimsel makale artículo científico publicado en 2008 artigo científico (publicado na 2008) 2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած научни чланак научная статья vedecký článok 2008年論文 мақолаи илмӣ 2008 թվականի նոյեմբերին հրատարակված գիտական հոդված naučni članak 2008年論文 vědecký článek מאמר מדעי scienca artikolo 2008年論文 مقالهٔ علمی vetenskaplig artikel 2008年论文 บทความทางวิทยาศาสตร์ artículu científicu espublizáu en 2008 2008年论文 tudományos cikk artigo científico (publicado na 2008) artikulong pang-agham научна статия articolo scientifico artykuł naukowy 2008年论文 bài báo khoa học наукова стаття, опублікована в листопаді 2008 articol științific
p:P577
wds:Q34600089-557FDB61-3FCD-457E-8246-85DC96B7A269
wdt:P577
2008-11-10T00:00:00Z
p:P407
wds:Q34600089-6E6FDB29-8F68-405B-9D49-99BA8DDACB59
wdt:P407
wd:Q1860
p:P2860
wds:Q34600089-ED992822-A0AB-4CFD-857F-6F19E2CA4604 wds:Q34600089-F4827520-AE4F-41D5-9C14-09A93D257C98 wds:Q34600089-B8B3CE81-B78C-499F-BC63-07705356203C wds:Q34600089-C0EC52A1-F3F3-4839-8C8C-EB450E9E9F1D wds:Q34600089-C1E0D98B-A2FB-4885-9F03-C7EA7BF415DD wds:Q34600089-C4848680-5DE4-48F1-8CE5-5710C0D18A1E wds:Q34600089-C54CB83B-325E-4F8E-ADFA-15BDA96EC151 wds:Q34600089-CE6FB677-1646-437C-806B-70CC68E5E83E wds:Q34600089-8D8A358F-53DA-40C8-9DB2-63239DA66D87 wds:Q34600089-A0A162C6-08C0-4325-8C81-9E2FA79BADBA wds:Q34600089-5B5FCD7E-9A10-4272-987A-44021BAC37C1 wds:Q34600089-612A0816-7CF4-4139-A935-BDF91A6983BA wds:Q34600089-76D81A25-5AA0-4D24-A5F1-971D1EC03580 wds:Q34600089-76F2D36D-24DB-46AA-B3FF-19F69CE45ADE wds:Q34600089-2014062C-1FFB-41BF-8CF4-0698A75A7E10 wds:Q34600089-3B7B2E69-8C5B-4DA8-BE49-9ACEDCDDAEDE wds:Q34600089-4659845D-BDC7-4276-8E34-2CF489D0DE62 wds:Q34600089-013CF4D4-533A-42CB-BB4B-1F19278000F0 wds:Q34600089-08A4213A-372F-49FF-926C-E950FE5B5BDF wds:Q34600089-158CEC64-88CF-4BFE-B069-C28DF61E0E72 wds:Q34600089-1F1623BD-1725-457C-8561-260B07F722FB wds:Q34600089-2002770E-D7CD-4A35-BBD9-AA8F333B47D7
wdt:P2860
wd:Q33332939 wd:Q43241008 wd:Q34507305 wd:Q38502534 wd:Q73494797 wd:Q44566602 wd:Q74148163 wd:Q46937324 wd:Q44357402 wd:Q52905241 wd:Q33376446 wd:Q24246409 wd:Q43918783 wd:Q36445957 wd:Q34522443 wd:Q34585566 wd:Q33344271 wd:Q40684881 wd:Q56891369 wd:Q48261802 wd:Q33491767 wd:Q48469829
p:P2093
wds:Q34600089-1F73DC46-E994-4648-AE92-472A96BCB491 wds:Q34600089-02387EDE-047F-4592-BDE9-311DFB6D91C7 wds:Q34600089-73D9908F-1310-438D-A9EE-582FBED50493 wds:Q34600089-5B55ECBE-B234-41B6-8CAF-8A0667F1E99C wds:Q34600089-D788C8AC-2484-4F91-92E5-771C8F7D2B06 wds:Q34600089-F9F02F2F-A824-4425-8A02-CA0331E3F06A wds:Q34600089-EDBB4DC3-5167-443B-8037-D8FFDB2E5A45
wdt:P2093
Gary I Cohen Jessie Hsu John M Kirkwood Michael B Atkins Lawrence E Flaherty Sandra Lee Jeffrey A Sosman
rdfs:label
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c
skos:prefLabel
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c
schema:name
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c
p:P50
wds:Q34600089-A56F0492-CC19-4706-90C1-F3BF97086C53 wds:Q34600089-DC6D753B-0312-4A51-80A0-887368F5E795
wdt:P50
wd:Q5330089 wd:Q100288223
p:P1476
wds:Q34600089-FEB8B314-AA28-4CEE-83F1-CE40E8D523D4
wdt:P1476
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c
p:P304
wds:Q34600089-838A9531-D0B2-48A7-BC61-7DF720DF9E7B
wdt:P304
5748-5754
p:P31
wds:Q34600089-7A69E1C8-39AA-4331-8F19-B0A10BD1ABD4
wdt:P31
wd:Q13442814
p:P921
wds:Q34600089-25087EB5-4B23-46CC-BED2-EB7A0BFD3B3B wds:Q34600089-78C6FF48-1CBC-4766-85CD-B29243A2AFF9 wds:Q34600089-f07a393a-ac1c-4585-bfea-875d37a3fb6b wds:Q34600089-8D90D08E-2F30-4974-B8BD-201F541F4F8D wds:Q34600089-917E0526-D92E-43DB-B68D-53245622D5C3 wds:Q34600089-DA10895A-EA7F-4A37-9A4B-2401D87CE39E
wdt:P921
wd:Q416975 wd:Q194908 wd:Q181600 wd:Q282629 wd:Q42824827 wd:Q412415
p:P698
wds:Q34600089-2CA02106-1FED-4928-AB23-67187BD6107C
wdtn:P698
n9:19001327
wdt:P698
19001327
p:P1433
wds:Q34600089-71ADFFB6-0E65-4271-A730-50C5E4FA1071
wdt:P1433
wd:Q400292
p:P433
wds:Q34600089-E16908B5-FAF7-4F50-AAA4-F33C6AAA7D06
p:P478
wds:Q34600089-82059518-E6E9-4A52-BD25-B795405AC7F7
wdt:P433
35
wdt:P478
26
p:P356
wds:Q34600089-323607EA-5019-47AC-89B0-611806CA9E0A
wdtn:P356
n12:JCO.2008.17.5448
wdt:P356
10.1200/JCO.2008.17.5448
p:P932
wds:Q34600089-068F7235-546E-48AF-B8C3-3AB148D2F142
wdt:P932
2645104